IP Library Granted Patent US 9,339,556
Granted Patent B2
US 9,339,556 · App. 13/927,437 · Granted May 17, 2016

Activation of human antigen-presenting cells through dendritic cell lectin-like oxidized LDL receptor-1 (LOX-1)

Inventors: Jacques F. Banchereau (Dallas, TX); SangKon Oh (Baltimore, MD); Gerard Zurawski (Midlothian, TX); Sandra Zurawski (Midlothian, TX); Dapeng Li (Dallas, TX)
Assignee: Baylor Research Institute
A61K47/48369C07K16/28A61K2039/55516C07K2317/92C07K2319/01C07K2319/33
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,339,556
App. No.
13/927,437
Granted
May 17, 2016
Kind
B2
Abstract

The present invention includes compositions and methods for targeting the LOX-1 receptor on immune cells and uses for the anti-LOX-1 antibodies.

Claims (13)

1. A LOX-1-specific antibody linked to one or more antigens; wherein the antibody comprises the variable regions of SEQ ID NOS:7 and 8.

2. The antibody of claim 1 , wherein the antibody is in a fusion protein with one half of a cohesin-dockerin binding pair.

3. The antibody of claim 2 , further comprising a complementary half of the cohesin-dockerin binding pair that is a fusion protein with an antigen.

4. The antibody of claim 1 , wherein the antibody comprises the heavy and light chain of SEQ ID NOS:7 and 8.

5. The antibody of claim 1 , wherein the antigen is a viral antigen, bacterial antigen, fungal antigen, protozoal antigen, parasitic antigen, tumor antigen or antigen involved in autoimmune disease or allergy and graft rejection.

6. The antibody of claim 1 , wherein the antibody is humanized.

7. The antibody of claim 1 , wherein the antigen is a human immunodeficiency virus (HIV) antigen.

8. The antibody of claim 7 , wherein the HIV antigen is a gene product of the gag gene, a gene product of the pol gene, a gene product of the env gene, the Nef protein, or reverse transcriptase.

9. A LOX-1-specific antibody linked to one or more antigens; wherein the antibody comprises all the antigen combining regions of SEQ ID NOS:7 and 8.

10. The antibody of claim 9 , wherein the antigen is a viral antigen, bacterial antigen, fungal antigen, protozoal antigen, parasitic antigen, tumor antigen or antigen involved in autoimmune disease or allergy and graft rejection.

11. The antibody of claim 9 , wherein the antibody is humanized.

12. The antibody of claim 9 , wherein the antigen is a human immunodeficiency virus (HIV) antigen.

13. The antibody of claim 12 , wherein the HIV antigen is a gene product of the gag gene, a gene product of the pol gene, a gene product of the env gene, the Nef protein, or reverse transcriptase.

Assignments (2)
CONFIRMATORY LICENSE Recorded Mar 6, 2018
From: BAYLOR RESEARCH INSTITUTE
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 045511/0528 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 24, 2014
From: BANCHEREAU, JACQUES; OH, SANGKON; ZURAWSKI, GERARD; ZURAWSKI, SANDRA; LI, DAPENG
To: BAYLOR RESEARCH INSTITUTE
Reel/Frame 032506/0665 →
Continuity (3)
Division 12036138 · Feb 22, 2008
Provisional Application 60891424 · Feb 23, 2007
Related Publication 20140120617A1 · May 1, 2014